GSK
DTC Marketing

A focus on diseases for which it believes it can develop more valuable drugs

Feb/04/2010 04:03 Filed in: Business of health #in
images
GlaxoSmithKline said it will stop research into new antidepressants and focus on diseases for which it believes it can develop more valuable drugs, a major shift for a company that developed some of the biggest-selling antidepressants of the past 20 years. The key question is "valuable to who" , investors or patients ? Maybe the reason is because physicians and patients are buying the marketing that led to a lot of people taking antidepressant medications ?

Read More...

Tags:

|

More Stuff